Skip to content
Our team

Science-Driven Leadership

Allotar brings together expertise in computational structural biology, biophysics, artificial intelligence and drug discovery to build a next-generation platform for precision allosteric drug discovery.

Team

Meet the team

Executive team
Pemra Doruker, PhD

Pemra Doruker, PhD

Co-founder, CEO

Leader in computational structural biology, multi-scale modeling/simulations, protein dynamics and allosteric drug design. Sets scientific direction and oversees the development of methods that translate protein dynamics into druggable allosteric sites.

LinkedIn ↗
Fidan Sumbul, PhD

Fidan Sumbul, PhD

Co-founder, COO & CSO

Biophysicist in protein dynamics, molecular simulation, single-molecule measurement and machine learning. Leads platform strategy and execution, from target selection through AI-guided design to experimental validation.

LinkedIn ↗
Yenel Yildirim

Yenel Yildirim

CTO

Senior engineering leader with experience building scalable cloud and computational platforms at Microsoft and Amazon.

LinkedIn ↗
Science at the Core

Allotar is built on peer-reviewed research in protein dynamics and allostery by our co-founders.

Explore the publications behind AllotarX™
Insights

News & Updates

Allotar awarded $504K NIH SBIR Phase I grant to advance selective Alzheimer’s therapeutics

The National Institute on Aging backs Allotar’s AllotarX™-driven program to discover selective allosteric modulators for Alzheimer’s disease.

Show more

Research reported here is supported by the National Institute on Aging of the National Institutes of Health under Award Number R43AG102306. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Allotar Therapeutics launches to unlock allosteric medicines

A new company turning protein dynamics into selective, validated therapeutics.

Future Opportunities at Allotar

We’re assembling world-class talent in computational physics, structural biology, AI, and drug discovery to redefine how therapeutics are discovered through dynamic biology.